Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 27.05.2025       Formycon AG

Press Release // May 27, 2025   Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada FYB202/Otulfi™ is now commercially available in Canada in both subcutaneous and intravenous formulations Launch expands market presence beyond the U.S. and Europe, offering broader treatment  [ … ]
Mon, 19.05.2025       Formycon AG

Press Release // May 19, 2025 Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)  Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated F [ … ]
Mon, 12.05.2025       Formycon AG

Press Release // May 12, 2025 Formycon reports strong operational performance and financial results for first quarter of 2025 Strong operational start to the year with market approvals for FYB203 (Aflibercept) in Europe and the United Kingdom as well as new commercialization partnerships with Teva and Lotus Encouraging market launch of FYB202/Ot [ … ]
Wed, 07.05.2025       Formycon AG

Presse Release // May 7, 2025Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences   Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results for the first quarter of 2025 on May 12, 2025. The Management [ … ]
Thu, 27.03.2025       Formycon AG

 Press Release // March 27, 2025   Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position Group revenue exceeds forecast with €69.7 million (guidance: €55.0 million to €65.0 million)   Group EBITDA at €-13.7 million also better than expected (guidance: €-25.0 mil [ … ]
Mon, 24.03.2025       Formycon AG

 Press Release // March 24, 2025   Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today announced details of the conference call for the release of the fisca [ … ]
Mon, 03.03.2025       Formycon AG

Press Release // March 3, 2025   FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous formulations in the United States and the European Union Patient transition to Otulfi® supported by comparable effic [ … ]
Tue, 25.02.2025       Formycon AG

Press Release // February 25, 2025   Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization [ … ]
Mon, 24.02.2025       Formycon AG

Company Name: Formycon AG ISIN: DE000A1EWVY8   Reason for the research: Update Recommendation: Buy from: 24.02.2025 Target price: €46 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analyst Simo [ … ]
Thu, 20.02.2025       Formycon AG

 Press Release // February 20, 2025   Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin   Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of the comparative data of the ustekinumab biosimilar FYB202 at this year's Congress of the European Croh [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Wednesday, 28.05.2025, Calendar Week 22, 148th day of the year, 217 days remaining until EoY.